Diabetes drug withdrawn after reports of hepatic events

BMJ 1997; 315 doi: (Published 13 December 1997) Cite this as: BMJ 1997;315:1559
  1. Jacqui Wise
  1. BMJ

    The new diabetes drug troglitazone (Romozin) has been withdrawn from the market in Britain after an increasing number of reports of severe hepatic adverse events. The Food and Drug Administration in the United States, however, has decided that the benefits of treatment outweigh the risks, provided that patients receiving troglitazone are monitored frequently for …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription